

1 **Risk Factors for ICU Admission, Mechanical Ventilation and Mortality in Hospitalized**
2 **Patients with COVID-19 in Hubei, China.**

3 Hong Gang Ren^{1,2} M.D., Ph.D., Xingyi Guo² M.D., Ph.D., Kevin Blighe³ B.Sc. (Hons.), Ph.D.,
4 Fang Zhu⁴ M.D., Ph.D., Janet Martin⁴ PharmD, MSc (HTA), Luqman Bin Safdar⁵ M.Sc., M.Phil.,
5 Pengcheng Yang⁶ M.D., Dao Wen Wang¹ M.D., Ph.D., Ph.D., Qinyong Hu⁶ M.D., Ph.D., Nan
6 Huo⁷ M.D., Ph.D., Justin Stebbing⁸, MA FRCP FRCPath PhD, Davy Cheng⁴ M.D., FRCPC.

7 **Author Affiliations:**

8 ¹ Department of Internal Medicine, Tongji Medical College, Huazhong University of Science and
9 Technology, Wuhan, China

10 ² Division of Epidemiology, Department of Medicine, Vanderbilt Epidemiology Center,
11 Vanderbilt University School of Medicine, Nashville, USA

12 ³ Clinical Bioinformatics Research Ltd., London, UK.

13 ⁴ Department of Anesthesia & Perioperative Medicine, Centre for Medical Evidence, Decision
14 Integrity and Clinical Impact and Department of Epidemiology & Biostatistics, Western
15 University, London, Ontario, Canada.

16 ⁵ The Key Laboratory of Biology and Genetic Improvement of Oil Crops, Oil Crops Research
17 Institute, Chinese Academy of Agricultural Sciences, The Ministry of Agriculture and Rural
18 Affairs, Wuhan 430062, China.

19 ⁶ Cancer Center, Renmin Hospital of Wuhan University, No. 99, Zhangzhidong Road, Wuchang
20 District, Wuhan, China.

21 ⁷ Department of Epidemiology, Health Sciences Research, Mayo Clinic, Rochester, Minnesota,
22 USA.

23 ⁸ Department of Surgery and Cancer, Division of Cancer, Imperial College London,
24 Hammersmith Hospital Campus, Du Cane Road, London, UK.

25

26 **Corresponding Authors:**

27 **Professor Dao Wen Wang,**

28 Department of Internal Medicine, Tongji Medical College,
29 Huazhong University of Science and Technology, Wuhan, China.

30 TEL: +86-010-66937120

31 Email: daowen.wang@foxmail.com

32 **Professor Qingyong Hu,**

33 Cancer Center, Renmin Hospital of Wuhan University, No. 99,
34 Zhangzhidong Road, Wuchang District, Wuhan, China.

35 Email: rm001223@whu.edu.cn

36 **Nan Huo,**

37 Department of Epidemiology, Health Sciences Research, Mayo
38 Clinic, Rochester, Minnesota, USA.

39 Email: huo.nan@mayo.edu

40 **Kevin Blighe,**

41 Clinical Bioinformatics Research Ltd., London, UK.

42 Email: kevin@clinicalbioinformatics.co.uk

43 **Professor Davy Cheng,**

44 Department of Anesthesia & Perioperative Medicine, Centre for
45 Medical Evidence, Decision Integrity and Clinical Impact and
46 Department of Epidemiology & Biostatistics, Western University,
47 London, Ontario, Canada.

48 Email: davy.cheng@uwo.ca

49 **Keywords:** COVID-19, CFR, ICU admission, mechanical ventilation, glucocorticoid

50

51 **Purpose:** To examine the risk factors for Intensive Care Unit (ICU) admission, mechanical
52 ventilation and mortality in hospitalized patients with COVID-19.

53 **Methods:** This was a retrospective cohort study including 432 patients with laboratory-
54 confirmed COVID-19 who were admitted to three medical centers in Hubei province from
55 January 1st to April 10th 2020. Primary outcomes included ICU admission, mechanical
56 ventilation and death occurring while hospitalized or within 30 days.

57 **Results:** Of the 432 confirmed patients, 9.5% were admitted to the ICU, 27.3% required
58 mechanical ventilation, and 33.1% died. Total leukocyte count was higher in survivors compared
59 with those who died (8.9 vs $4.8 \times 10^9/l$), but lymphocyte counts were lower (0.6 vs $1.0 \times 10^9/l$).
60 D-dimer was significantly higher in patients who died compared to survivors (6.0ug/l vs 1.0ug/l ,
61 $p < 0.0001$). This was also seen when comparing mechanically versus non-mechanically-ventilated
62 patients. Other significant differences were seen in AST, ALT, LDH, total bilirubin and creatinine
63 kinase. The following were associated with increased odds of death: age > 65 years (adjusted
64 hazard ratio (HR 2.09, 95% CI 1.02-4.05), severe disease at baseline (5.02, 2.05-12.29), current
65 smoker (1.67, 1.37-2.02), temperature $> 39^\circ$ C at baseline (2.68, 1.88-4.23), more than one
66 comorbidity (2.12, 1.62-3.09), bilateral patchy shadowing on chest CT or X-ray (3.74, 1.78-9.62)
67 and organ failure (6.47, 1.97-26.23). The following interventions were associated with higher
68 CFR: glucocorticoids (1.60, 1.04-2.30), ICU admission (4.92, 1.37-17.64) and mechanical
69 ventilation (2.35, 1.14-4.82).

70 **Conclusion:** Demographics, including age over 65 years, current smoker, diabetes, hypertension,
71 and cerebrovascular disease, were associated with increased risk of mortality. Mortality was also
72 associated with glucocorticoid use, mechanical ventilation and ICU admission.

73 **Take-Home Message:** COVID-19 patients with risk factors were more likely to be admitted into
74 ICU and more likely to require mechanical ventilation.

75

76 **Declarations:**

77 **Funding:** This study was funded by Beijing Municipal Natural Science Foundation General
78 Program (7192197), National Key Research and Development Project (2018YFC2002400) and
79 National Natural Science Foundation of China (81700490).

80 **Conflicts of interest:** JS conflicts can be found at: <https://www.nature.com/onc/editors>. None
81 are relevant here. No other authors declare a conflict.

82 **Availability of data and material:** The corresponding author had full access to all the data in
83 the study and had final responsibility for the decision to submit for publication.

84 **Code availability:** Not applicable.

85 **Authors' contributions:** All authors made a significant contribution to merit authorship, either
86 by writing and editing the manuscript text, and/or analyzing data, and each has seen and
87 approved the final version. HR, FZ, JM, PY, QH, collected the epidemiological and clinical data.
88 HR, JM, DC summarized all data. HR, DW drafted the manuscript. HR, LBS, KB, XG, DW, NH,
89 JS, DC edited the final manuscript.

90

91 **INTRODUCTION**

92 As of May 5 2020, the COVID-19 pandemic has led to over 3.6 million cases of infection and
93 over 270,000 deaths globally, according to the World Health Organization. In earlier reports, the
94 case fatality rate (CFR) of critically ill patients with COVID-19 has been as high as 61.5%¹⁻¹¹.
95 COVID19 exhibits distinctive features from acute respiratory distress syndrome (ARDS)¹² and,
96 although a number of therapeutic options exist, including lopinavir/ritonavir combination,
97 remdesivir, arbidol, convalescent plasma, traditional Chinese medicine, and stem cell infusion
98 remain experimental, there is a lack of evidence regarding their net benefits and risks. To date,
99 there are no specific drugs or therapeutic interventions which have been proven to reduce
100 mortality, nor is the development of an effective vaccine expected this year. However, guidelines
101 from a panel of experts have recently emerged, covering many aspects relating to critical care
102 management of COVID-19 patients¹³.

103 Currently, few studies have focused on the risk factors for death in hospitalized patients with
104 COVID-19¹⁰⁻¹¹. Frailty index (FI) has been examined as a potentially useful measure of
105 outcome¹⁴. Also, in a study of 191 hospitalized patients, Zhou et al found that older age, higher
106 sequential organ failure assessment score (SOFA), and D-dimer over 1µg/L were independent
107 predictors of death in patients with COVID-19.¹¹ A study of 52 critically ill patients with
108 COVID-19 found that increased age, development of ARDS, and mechanical ventilation were
109 associated with mortality. However, early studies on mortality and associated risk factors have
110 been plagued by incomplete data, lack of longitudinal follow-up and small sample size, since
111 many COVID-19 patients remained hospitalised at time of publication.

112 The objective of this study was to compare patient demographics, clinical characteristics, and
113 management strategies between COVID-19 fatalities and survivors, and to identify risk factors
114 for Intensive Care Unit (ICU) admission, mechanical ventilation and mortality in hospitalized
115 patients with confirmed COVID-19.

116

117 **METHODS**

118 **Study population and data sources**

119 This was a retrospective cohort study using electronic medical record data from January 1st to
120 February 29th, 2020 of 432 inpatients with confirmed COVID-19 from three academic medical
121 centers in Hubei province (Xiehe medical center, Hannan medical center, and Enshi medical
122 center). All of these three medical centers have fully functional ICU capabilities. Patients who
123 were diagnosed with COVID-19 before January 1st or after February 29th were excluded due to
124 lack of standardized treatments. Patients with missing data regarding ICU admission or
125 mechanical ventilator use were excluded from this study as well.

126 All patients with COVID-19 were identified based on WHO interim guidance. The ‘index date’
127 was the date when the patients were first diagnosed with COVID-19 between January 1st,to
128 February 29th, 2020. This study was approved by the institutional review boards of all
129 participating medical centers.

130 **Main Outcome Measures**

131 The main outcomes collected in all hospitalized and confirmed COVID-19 hospital patients were
132 CFR, ICU admission rate, and mechanical ventilation usage after hospital admission. Mortality
133 was defined by death certificates. All COVID-19 patients were followed up to hospital discharge
134 or death at the end of study period (February 29th, 2020).The clinical risk factors for ICU
135 admission, mechanical ventilation (both invasive and non-invasive ventilator), and mortality
136 were compared. Patients who did not have these outcomes were categorized as “none.”

137 **Covariates**

138 All demographic characteristics were determined at index date, including age, gender, race and
139 smoking history. Individual-level data such as exposure history, observation days before
140 hospitalization, the number of symptoms at index date, diagnostic investigations (lab and
141 radiology), all medical procedures, and prescriptions were retrieved from electronic medical
142 records. Comorbidities were also included as clinical covariates.

143 Clinical symptoms at the index date included fever, nasal congestion, headache, cough, sore
144 throat, sputum production, fatigue, shortness of breath, breathing difficulties, nausea or vomiting,
145 diarrhea, anorexia, abdominal pain, and myalgia or arthralgiachrchan. Lab tests included

146 complete blood count, coagulation profile, serum biochemical tests (renal and liver function,
147 creatine kinase, lactate dehydrogenase, and electrolytes), myocardial enzymes, interleukin-6 (IL-
148 6), and procalcitonin. The comorbidities of patients with COVID-19 included coronary heart
149 disease, diabetes, COPD, hypertension, cerebrovascular disease, chronic kidney disease, chronic
150 liver disease, cancer, and others.

151 **Statistical Analyses**

152 Continuous and categorical variables are presented as median (IQR) and n (%), respectively. We
153 used the Mann-Whitney U test, χ^2 test, or Fisher's exact test to compare differences between
154 survivors and non-survivors where appropriate. Multivariable logistic regression models were
155 conducted to identify factors associated with ICU admission and mechanical ventilation in each
156 cohort, reported as adjusted odds ratios (AOR) and their corresponding 95% confidence intervals
157 (CI).

158 After patients were diagnosed, the time to death or the time to hospital discharge was examined
159 using the Fine-Gray cumulative incidence functions (CIF). In addition, time to the main outcome
160 - death - was further examined in subgroups of both cohorts by age, gender, comorbidities, and
161 geographic region of residence. Finally, a multivariate Cox proportional hazard model was used
162 to identify factors associated with the cumulative incidence of mortality. Two sensitivity
163 analyses were performed, first by excluding patients with any comorbidity, and second by using
164 multivariate cause-specific hazards models to identify factors associated with the cumulative
165 incidence of mortality in our study. All analyses were conducted using SAS version 9.4 (SAS
166 Institute, Inc., Cary, NC) at a significance level of $p < 0.05$.

167

168 **RESULTS**

169 Of the 432 confirmed COVID-19 patients, 9.53% were admitted to the ICU, 27.3% required
170 mechanical ventilation and 33.1% died (Table 1). There were significantly higher proportions of
171 COVID-19 patients of advanced age, more severe disease, and more comorbidities across all
172 three complication outcomes (mortality, ICU admission and mechanical ventilation). In addition,
173 greater proportions of patients who died were current smokers, with symptoms of diarrhea,
174 fatigue, breathing difficulties at the time of diagnosis, and ground-glass or bilateral opacities on
175 chest imaging.

176 **Adjusted Cox proportional hazard model for CFR**

177 Table 2 displays the analysis from multivariable Cox proportional hazards models of factors
178 associated with mortality during the 30 days after COVID-19 patients were hospitalized. Age
179 over 65 years (adjusted hazard ratio (HR) 2.09, 95% CI 1.02-4.05), severe disease at index date
180 (HR 5.02, 95% CI 2.05-12.29), current smoker (HR 1.67, 95% CI 1.37-2.02), temperature >39°C
181 at index date (HR 2.68, 95% CI 1.88-4.23), multiple comorbidities (diabetes, hypertension, CVA)
182 (HR 2.12, 95% CI 1.62-3.09), bilateral patchy shadowing of chest CT or X-ray (HR 3.74, 95%
183 CI 1.78-9.62), organ failure (HR 6.47, 95% CI 1.97-26.23), high leukocyte count (HR 2.19, 95%
184 CI 1.11-4.31), and a high D-dimer level (HR 1.87, 95% CI 1.87-3.38)] were associated with
185 higher risk of mortality. The following interventions were associated with higher adjusted hazard
186 ratio for mortality: mechanical ventilation (HR 2.35, 95% CI 1.14-4.82), ICU admission (HR
187 4.92, 95% CI 1.37-17.64), and treatment with glucocorticoids (HR 1.60, 95% CI 1.04-2.30).

188 **Adjusted Logistic Regression Model for ICU Admission and Mechanical Ventilation**

189 Results from multivariate logistic regression analysis models showed that subjects who were
190 older than 65 years, had more than one comorbidity, or had patchy bilateral shadowing of chest
191 CT or X-ray were more likely to require mechanical ventilation or be admitted into the ICU
192 (Table 2). Similarly, patients who were older than 65 years, current smokers, had more than one
193 comorbidity, organ failure, or a leukocyte count $\geq 4 \times 10^9$ per liter were more likely to require
194 mechanical ventilation (Table 1).

195 Sensitivity analyses using cause-specific hazard models for the 432 hospitalized patients found
196 similar results for mortality. After excluding those patients with comorbidities, the risk factors

197 associated with mortality and mechanical ventilator support were consistent with the primary
198 findings. Due to the small number of patients admitted to ICU, sensitivity analysis was not
199 possible in this subgroup.

200

201 **DISCUSSION**

202 This multi-center retrospective cohort study of 432 patients with confirmed COVID-19 admitted
203 to three academic medical centers in Hubei province, China, from Jan 1st – Feb 29th, 2020,
204 shows that 33.1% patients died within 30 days after COVID-19 diagnosis. The risk of death in
205 hospitalized patients is far greater than that of the total population diagnosed with COVID-19,
206 since overall CFR include both hospitalized and non-hospitalized cases, and the majority of
207 confirmed cases of COVID are less severe and do not require hospitalization. As of May 5, 2020,
208 there were 57,682 COVID-19 cases and 3130 COVID-19 related deaths in Hubei province. The
209 reported CFR across Hubei province is 5.1%, compared to a global CFR of 4.1%.

210 The difference in CFR may be in part due to the fact that Union Hospital medical center admitted
211 more elderly patients than others during the the earlier period of the COVID-19 outbreak in
212 China. This is supported by our findings in this study that positive COVID-19 patients who were
213 older than 65 years old admitted to hospitals is associated with a 2-fold increased risk of death
214 after 30 days.

215 In contrast to a study by Zhou et al of inpatients at different hospitals in Wuhan,¹¹ our study
216 identifies a number of other factors associated with increased risk of death, ICU admission, and
217 mechanical ventilation that may be helpful for clinicians assessing prognosis and risk cohorting.
218 The higher risk of death and mechanical ventilation in current smokers is a notable finding, and
219 may be relevant in countries where smoking is common. It may represent a potentially
220 modifiable risk factor, and a may serve as an impetus to encourage smoking cessation or develop
221 smoking prevention programs to mitigate risks during coronavirus outbreaks. In addition, our
222 study suggests that patients who present to hospital with increased age, multiple comorbidities,
223 higher temperature, higher leukocyte count, higher D-dimer, organ failure, and radiologic
224 abnormalities should be assessed as a cohort at higher risk of requiring ICU, ventilatory support
225 and death.

226 It is also notable that diarrhea was proportionately higher in patients who died during
227 hospitalization (Table 1), however, this symptom was not individually assessed in the adjusted
228 proportional analysis, and remains to be explored in future analyses. A recent study of 204
229 patients with confirmed COVID-19 in Hubei found that 48.5% of patients presented to hospital

230 with gastrointestinal symptoms as their chief complaint, although the association with death was
231 not explored.¹⁵

232 The association of higher D-dimer levels (> 1 µg/mL) and bilateral opacities on chest imaging
233 with adverse outcomes and death is in agreement with previous studies of Severe Acute
234 Respiratory Syndrome CoV (SARS-CoV) and Middle East Respiratory Syndrome CoV (MERS-
235 CoV) that described massive inflammatory cell infiltration within the lower airway¹⁶ leading to
236 pro-inflammatory cytokine/chemokine storm.¹⁷ This rapidly evolving immunological
237 dysfunction or dysregulation can lead to acute lung injury (ALI) and ARDS. The 2019 novel
238 coronavirus (SARS-CoV-2) has a similar genome, and may share similar pathophysiologic
239 findings, although SARS-CoV may cause even more severe cytokine storm resulting in its higher
240 CFR. Increased D-dimer concentrations among patients with pneumonia have been observed in
241 studies due to increased coagulation activity.¹⁸ Microvascular thrombosis can result from
242 excessive netosis observed in COVID-19 patients.

243 Although activation of the inflammatory cascade appears to contribute to adverse outcomes, we
244 found that corticosteroids were associated with a higher risk of death, ICU admission, and
245 mechanical ventilation. In 2003 and 2004, corticosteroids were widely used to treat SARS, first
246 in mainland China and then in Hong Kong and beyond. The hypothesis of using corticosteroids
247 was to reduce “cytokine storm” related acute lung injury, resulting from release of early
248 response cytokines such as interferon-gamma (IFN-γ), tumor necrosis factor (TNF-α),
249 interleukin 1 (IL-1), and interleukin 6 (IL-6).¹⁷⁻²⁰ However, a number of observational studies
250 have shown an association of corticosteroids with poorer outcomes in COVID-19 and the
251 balance of evidence questions their use for treatment of human coronaviruses including SARS-
252 CoV, MERS-CoV, and COVID-19.²⁰¹⁹⁻²⁰ The reasons for the adverse association could be that
253 (1) corticosteroids are harmful overall given the net clinical impact on other unrecognised
254 physiologic mechanisms, despite reducing the inflammatory response, or (2) more severely
255 affected patients are more likely to be prescribed corticosteroids and die, and selection biases
256 remain in our mortality estimates even after calculating adjusted hazards ratios. These results
257 emphasize the importance of the data from the RECOVERY (Randomised Evaluation of COVid-
258 19 thERapY) trial (www.recoverytrial.net/), which found that dexamethasone reduced the risk of
259 28-day mortality. Our study is strictly not a direct comparison to that of RECOVERY, and our

260 results actually highlight just how important it is to have a controlled trial surrounding the ‘when’
261 and the ‘to whom’ one should commence / administer corticosteroid treatment. Current
262 recommendations are to use low-dose corticosteroid therapy in patients with COVID-19 and
263 refractory shock¹³.

264 In line with previous studies of SARS-CoV and MERS-CoV,^{21,22} our findings also provide
265 evidence for higher risk of death with increasing age in hospitalized patients with COVID-19. In
266 addition to the higher risk of mortality in elderly patients, we also found they were more likely to
267 be admitted into ICU and more likely to require mechanical ventilation. We also found a higher
268 likelihood of mortality in patients with multiple morbidities, such as coronary heart disease,
269 which has previously been associated with poor outcomes of respiratory viral infections, and
270 diabetes, which has previously been linked to reduced immune system function.²³⁻²⁵

271 Other interesting findings were that a higher proportion of patients with positive exposure history
272 presented with more severe disease. The reason for this association is unclear.

273 **Strengths and Limitations**

274 Of the currently published COVID-19 observational studies on mortality to date, the sample size
275 of our study is among the largest. Despite that, it may still lack sufficient power to determine true
276 associations in our analysis. Furthermore, the treatment regimens across different centers may
277 differ, including ICU admission criteria, mechanical ventilation criteria and modalities, use of
278 antibiotics, antivirals, and other supportive interventions. Considering the retrospective
279 observational nature of our study, it is difficult to eliminate selection biases and remaining
280 confounders. For this reason, conclusions regarding the risk-benefit tradeoffs for interventions
281 including corticosteroids, antibiotics, antivirals, mechanical ventilation, and ICU admission
282 cannot be made from this analysis. However, this analysis is the best we can provide to enlighten
283 current outcomes related to approaches to treatment for COVID-19 that were utilized in Hubei
284 hospitals in early 2020. Due to subgroup limitations for each comorbidity, we combined all
285 comorbidities together for analysis. Larger studies are needed to further elucidate which patients
286 are at most risk of death, ICU, or require mechanical ventilation by specific co-morbidities.
287 Finally, this was a retrospective case series study that relied on abstracting data from clinical
288 charts. Accordingly, information was limited to that provided in the charts at the time of patient
289 care.

290 **CONCLUSION**

291 In hospitalized patients with confirmed COVID-19 in Hubei, the need for mechanical ventilation
292 and risk of death was high. A number of patient-level demographics were associated with
293 increased risk of mortality, including age over 65 years, current smoker, diabetes, hypertension,
294 and cerebrovascular disease. Clinical characteristics associated with mortality included
295 temperature $>39^{\circ}\text{C}$, diarrhea, fatigue, shortness of breath, breathing difficulties, higher disease
296 severity, organ failure, and ground-glass opacity or bilateral patchy shadowing on chest imaging.
297 Risk of mortality was also associated with mechanical ventilation and ICU admission.
298 Corticosteroid treatment was associated with increased mortality. These results underscore the
299 urgency of adequate prospective clinical trials to inform the role of, in particular, corticosteroids,
300 but also mechanical ventilation and ICU admission, in managing COVID-19. Results from the
301 RECOVERY trial have strongly indicated that timing of corticosteroid intervention is key.
302 Knowledge of baseline demographic risk factors and clinical predictors for adverse outcomes
303 may assist clinicians in optimally triaging patients presenting to hospital with COVID-19 during
304 this pandemic. Finally, our study's results are in line with those results coming from studies
305 published in the West²⁶⁻²⁸.

306

307 **References**

- 308 1. Bai Y, Yao L, Wei T, et al. Presumed Asymptomatic Carrier Transmission of COVID-19.
309 JAMA. 2020; 323: 1406-1407. .
- 310 2. Chan JF, Yuan S, Kok KH, et al. A familial cluster of pneumonia associated with the
311 2019 novel coronavirus indicating person-to-person transmission: a study of a family
312 cluster. Lancet. 2020. 395(10223): 514-523.
- 313 3. Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases
314 of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet.
315 2020. 395(10223): 507-513.
- 316 4. Coutard B, Valle C, de Lamballerie X, Canard B, Seidah NG, Decroly E. The spike
317 glycoprotein of the new coronavirus 2019-nCoV contains a furin-like cleavage site absent
318 in CoV of the same clade. Antiviral Res. 2020. 176: 1047-42.
- 319 5. Li JY, You Z, Wang Q, et al. The epidemic of 2019-novel-coronavirus (2019-nCoV)
320 pneumonia and insights for emerging infectious diseases in the future. Microbes Infect.
321 2020. 22(2): 80-85.
- 322 6. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel
323 coronavirus in Wuhan, China. Lancet. 2020. 395(10223): 497-506.
- 324 7. Lee PI, Hsueh PR. Emerging threats from zoonotic coronaviruses-from SARS and MERS
325 to 2019-nCoV. J Microbiol Immunol Infect. 2020 .(vol: pages)
- 326 8. Tang B, Bragazzi NL, Li Q, Tang S, Xiao Y, Wu J. An updated estimation of the risk of
327 transmission of the novel coronavirus (2019-nCov). Infect Dis Model. 2020. 5: 248-255.
- 328 9. Wu JT, Leung K, Leung GM. Nowcasting and forecasting the potential domestic and
329 international spread of the 2019-nCoV outbreak originating in Wuhan, China: a
330 modelling study. Lancet. 2020. 395(10225): 689-697.
- 331 10. Yang X, Yu Y, Xu J, et al. Clinical course and outcomes of critically ill patients with
332 SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective,
333 observational study. Lancet Respir Med. 2020 .(vol: pages)

- 334 11. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for
335 mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort
336 study. *Lancet*. 2020; 395: 1054-62. PMID:32171076
- 337 12. Gattinoni, L., Chiumello, D., Caironi, P. et al. COVID-19 pneumonia: different
338 respiratory treatments for different phenotypes?. *Intensive Care Med* 46, 1099–1102
339 (2020). <https://doi.org/10.1007/s00134-020-06033-2>
- 340 13 Alhazzani W, Møller MH, Arabi YM, Loeb M, Ng Gong M, Fan E, et al., Surviving
341 Sepsis Campaign: guidelines on the management of critically ill adults with Coronavirus
342 Disease 2019 (COVID-19), *Intensive Care Medicine* volume 46, pages 854–887 (2020).
- 343 14 Bellelli, G., Rebori, P., Valsecchi, M.G. et al. Frailty index predicts poor outcome in
344 COVID-19 patients. *Intensive Care Med* (2020). [https://doi.org/10.1007/s00134-020-](https://doi.org/10.1007/s00134-020-06087-2)
345 [06087-2](https://doi.org/10.1007/s00134-020-06087-2)
- 346 15. Pan L, Mu M, Ren HG, Yan P, Wang R, Yan J, et al. Clinical characteristics of COVID-
347 19 patients with digestive symptoms in Hubei, China: a descriptive, cross-sectional,
348 multicenter study. *Am J Gastroenterol* 2020 (published online April 14, 2020)
- 349 16. Rodelo JR, De la Rosa G, Valencia ML, Ospina S, Arango CM, Gómez CI, et al. D-dimer
350 is a significant prognostic factor in patients with suspected infection and sepsis. *Am J*
351 *Emerg Med*. 2012;30:1991-9. PMID:22795996
- 352 17. Cheung CY, Poon LL, Lau AS, Luk W, Lau YL, Shortridge KF, et al. Induction of
353 proinflammatory cytokines in human macrophages by influenza A (H5N1) viruses: a
354 mechanism for the unusual severity of human disease. *Lancet*. 2002;360:1831-
355 7. PMID:12480361
- 356 18. Milbrandt EB, Reade MC, Lee M, Shook SL, Angus DC, Kong L, et al. Prevalence and
357 significance of coagulation abnormalities in community-acquired pneumonia. *Mol Med*.
358 2009;15:438-45. PMID:19753144
- 359 19. Auyeung TW, Lee JS, Lai WK, Choi CH, Lee HK, Lee JS, et al. The use of corticosteroid
360 as treatment in SARS was associated with adverse outcomes: a retrospective cohort study.
361 *J Infect*. 2005;51:98-102. PMID:16038758

- 362 20. Russel CD, Millar JE, Baillie JK. Clinical evidence does not support corticosteroid
363 treatment for 2019-nCoV lung injury. *Lancet* 2020;395:473-5.
- 364 21. Choi KW, Chau TN, Tsang O, Tso E, Chiu MC, Tong WL, et al. Outcomes and
365 prognostic factors in 267 patients with severe acute respiratory syndrome in Hong Kong.
366 *Ann Intern Med.* 2003;139:715-23. PMID:14597455
- 367 22. Hong KH, Choi JP, Hong SH, Lee J, Kwon JS, Kim SM, et al. Predictors of mortality in
368 Middle East respiratory syndrome (MERS). *Thorax.* 2018;73:286-9. PMID:28724637
- 369 23. Corrales-Medina VF, Musher DM, Shachkina S, Chirinos JA. Acute pneumonia and the
370 cardiovascular system. *Lancet.* 2013;381:496-505. PMID:23332146
- 371 24. Udell JA, Zawi R, Bhatt DL, Keshtkar-Jahromi M, Gaughran F, Phrommintikul A, et
372 al. Association between influenza vaccination and cardiovascular outcomes in high-risk
373 patients: a meta-analysis. *JAMA.* 2013;310:1711-20. PMID:24150467
- 374 25. Blackburn R, Zhao H, Pebody R, Hayward A, Warren-Gash C. Laboratory-Confirmed
375 Respiratory Infections as Predictors of Hospital Admission for Myocardial Infarction and
376 Stroke: Time-Series Analysis of English Data for 2004-2015. *Clin Infect Dis.* 2018;67:8-
377 17. PMID:29324996
- 378 26. Grasselli G, Zangrillo A, Zanella A, Antonelli M, Cabrini L, Castelli A, et al., Baseline
379 Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to
380 ICUs of the Lombardy Region, Italy. *JAMA.* 2020 323(16):1574-1581.
- 381 27. Richardson S, Hirsch JS, Narasimhan M, Crawford JM, McGinn T, Davidson KW, and
382 the Northwell COVID-19 Research Consortium, Presenting Characteristics,
383 Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the
384 New York City Area. *JAMA.* 2020. 323(20):2052-2059.
- 385 28. Azoulay, E., Zafrani, L., Mirouse, A. et al. Clinical phenotypes of critically ill COVID-19
386 patients. *Intensive Care Med* (2020). <https://doi.org/10.1007/s00134-020-06120-4>
387
388

389 Table 1. Clinical Characteristics of the All Patients, According to the Mortality, ICU Admission, and Mechanical Ventilation

Characteristics	Mortality			ICU Admission			Mechanical Ventilation		
	Yes	No	P [*]	Yes	No	P [*]	Yes	No	P [*]
	N=143 (33.11%)	N = 289 (66.89%)		N=43 (9.53%)	N=389 (90.47%)		N=118 (27.31%)	N = 314 (72.69%)	
Age									
Median (IQR)—yr	68 (61 - 77)	51.0 (39 - 64)	<0.0001	64 (58 - 71)	57 (43 - 69)	0.0177	69 (60 - 77)	53.5 (40 - 65)	<0.0001
Distribution no./total no. (%)			<0.0001			0.04			<0.0001
≤ 50 yr	14 (9.79%)	137 (47.40%)		9 (20.93%)	142 (36.50%)		16 (13.56%)	135 (42.99%)	
51—65 yr	44 (30.77%)	91 (31.49%)		13 (30.23%)	122 (31.36%)		32 (27.12%)	103 (32.80%)	
≥ 66 yr	85 (59.44%)	61 (21.21%)		21 (48.84%)	125 (32.13%)		70 (59.32%)	76 (24.20%)	
Female sex no./total no. (%)	46 (32.17%)	97 (33.56%)	>0.05	29 (67.44%)	221 (56.56%)	>0.05	76 (64.14%)	174 (55.41%)	>0.05
COVID-19 Severity			0.009						<0.0001
Non-severe	46 (32.17%)	136 (47.06%)		3 (6.98%)	219 (56.30%)		5 (4.24%)	217 (69.11%)	
Severe	97 (67.83%)	153 (52.94%)		40 (93.02%)	170 (43.70%)		113 (95.76%)	97 (31.89%)	
Smoking history no./total no. (%)			0.041						0.03
Never smoked	125 (87.41%)	264 (91.35%)		38 (90.05%)	351 (90.23%)	>0.05	101 (85.59%)	288 (91.72%)	
Current smoker	18 (12.59%)	25 (8.65%)		5 (9.95%)	38 (9.77%)		17 (14.41%)	26 (8.28%)	
Exposure history									
Went to Wuhan	136 (95.10%)	150 (51.90%)	<0.0001	43 (100%)	243 (62.47%)	<0.0001	115 (97.46%)	175 (57.46%)	<0.0001
Went to seafood wholesale market	8 (5.59%)	12 (4.15%)	0.50	6 (13.95%)	14 (3.60%)	>0.05	7 (5.93%)	13 (4.14%)	
Contact with diagnosed patient	7 (4.90%)	37 (12.80%)	0.01	6 (13.95%)	38 (9.77%)	>0.05	7 (5.93%)	37 (11.78%)	0.07
Median waiting hospitalization period (IQR) - days	10 (6- 14)	7.0 (4 - 10)		9.5 (6 - 13)	7.0 (4 - 10)		7.0 (10 - 14)	7 (4 - 10)	
Fever on admission	124 (86.71%)	253 (87.54%)	0.81	37 (86.05%)	340 (87.40%)	>0.05	101 (85.59%)	276 (87.90%)	0.52
Median temperature (IQR) °C	38.6 (37.8 - 39.1)	38.0 (37.4 - 38.0)		38.9 (38.5 - 39.2)	38.2 (37.5 - 39)		38.5 (37.5 - 39)	38.2 (37.6 - 39)	

Distribution of temperature no./total no. (%)	<0.0001			0.0006			0.04
<37.5 °C	25 (17.48%)	77 (27.64%)	5 (11.63%)	97 (24.94%)	28 (23.73%)	74 (23.57%)	
37.5 - 39.0 °C	82 (57.34%)	187 (64.71%)	24 (55.81%)	245 (62.98%)	66 (55.93%)	203 (64.65%)	
>39.0 °C	36 (25.17%)	25 (8.65%)	14 (32.56%)	47 (12.08%)	24 (20.34%)	37 (11.78%)	

390

Characteristics	Mortality			ICU Admission			Mechanical Ventilation		
	Yes	No	P*	Yes	No	P*	Yes	No	P*
	N=143 (33.11%)	N = 289 (66.89%)		N=43 (9.53%)	N=389 (90.47%)		N=118 (27.31%)	N = 314 (72.69%)	
Symptoms - no. (%)									
Nasal congestion	1 (0.70%)	5 (1.73%)	0.39	0	6 (1.54%)	>0.05	1 (0.58%)	5 (1.59%)	0.56
Headache	6 (4.20%)	32 (11.07%)	0.02	3 (6.89%)	35 (9.00%)	>0.05	6 (5.08%)	32 (10.19%)	0.09
Cough	92 (64.34%)	208 (71.97%)	0.10	30 (69.77%)	270 (69.41%)	>0.05	72 (61.02%)	228 (72.61%)	0.02
Sore throat	4 (2.8%)	31 (10.73%)	0.0028	2 (4.65%)	33 (8.49%)	>0.05	4 (3.39%)	31 (9.87%)	0.09
Sputum production	60 (41.90%)	114 (39.45%)	0.62	17 (39.53%)	157 (40.36%)	>0.05	46 (38.98%)	128 (40.76%)	0.74
Fatigue	93 (65.03%)	125 (43.25%)	<0.0001	28 (65.12%)	190 (48.84%)	0.04	73 (68.86%)	145 (46.18%)	0.003
Shortness of breath	95 (66.43%)	89 (30.80%)	<0.0001	22 (51.16%)	162 (41.65%)	>0.05	71 (60.17%)	113 (35.99%)	
Breathing Difficulties	93 (65.03%)	42 (14.53%)	<0.0001	25 (58.14%)	110 (28.28%)	<0.0001	75 (63.56%)	60 (19.11%)	<0.0001
Nausea or vomiting	8 (5.59%)	18 (6.23%)	0.79	1 (2.33%)	25 (6.43%)	>0.05	4 (3.39%)	22 (7.01%)	0.16
Diarrhea	29 (20.28%)	25 (8.65%)	0.0006	7 (16.28%)	47 (12.08%)	>0.05	20 (16.95%)	34 (10.83%)	0.09
Anorexia	90 (62.94%)	192 (66.44%)	0.47	23 (53.49%)	259 (66.58%)	>0.05	66 (55.93%)	216 (68.79%)	0.01
Abdominal pain	6 (4.20%)	17 (5.88%)	0.46	1 (2.33%)	22 (5.66%)	>0.05	4 (3.39%)	19 (6.055)	0.27
Myalgia or arthralgia	25 (17.48%)	26 (9.00%)	0.01	12 (27.91%)	39 (10.03%)	0.0006	20 (16.95%)	31 (9.87%)	0.04
Median of Symptoms (IQR)	5 (4 - 7)	5 (3 - 6)		5 (4 - 7)	5 (3 - 6)		5 (3 - 7)	5 (4 - 6)	
Distribution of Symptoms - no. (%)			0.0008			0.47			0.04
0-2	10 (6.99%)	42 (14.53%)		6 (13.95%)	46 (11.83%)		14 (11.86%)	38 (12.10%)	
3-5	67 (46.85%)	152 (52.60%)		18 (41.86%)	201 (51.67%)		56 (47.46%)	163 (51.91 %)	
≥6	66 (46.15%)			19 (44.19%)	142 (36.50%)		48 (40.68%)	113 (35.99%)	
Highest Respiratory rate (IQR), breath / min	25 (20 - 30)	20 (20 - 20)		23 (20 - 30)	20 (20 - 23)		20 (25 - 30)	20 (20 - 21)	
Comorbidities - no. (%)									
Coronary artery disease	22 (15.38%)	30 (10.38%)	0.13	8 (18.60%)	44 (11.30%)		18 (15.25%)	34 (10.83%)	0.21

Diabetes	40 (27.97%)	28 (9.69%)	<0.0001	13 (30.23%)	55 (14.14%)	0.006	34 (28.81%)	34 (10.83%)	<0.0001
COPD	5 (3.50%)	4 (1.38%)	0.15	1 (2.33%)	8 (2.06%)	>0.05	6 (5.08%)	3 (0.96%)	0.007
Hypertension	59 (41.26%)	60 (20.76%)	<0.0001	16 (37.21%)	103 (26.48%)	>0.05	47 (39.83%)	72 (22.93%)	0.005
Cerebrovascular disease	13 (9.09%)	3 (1.04%)	<0.0001	3 (6.89%)	13 (3.34%)	>0.05	9 (7.63%)	7 (2.23%)	0.08
Chronic kidney disease	9 (6.29%)	8 (2.77%)	0.08	2 (4.65%)	15 (3.86%)	>0.05	8 (6.78%)	9 (2.87%)	0.06
Chronic liver disease	5 (3.50%)	6 (2.08%)	0.38	2 (4.65%)	9 (2.31%)	>0.05	2 (1.69%)	9 (2.87%)	0.49
Cancer	11 (7.69%)	12 (4.15%)	0.12	2 (4.65%)	21 (5.40%)	>0.05	6 (5.08%)	17 (5.41%)	0.89
Others	22 (15.38%)	39 (13.49%)	0.59	11 (25.58%)	50 (12.85%)	0.02	15 (12.71%)	46 (14.65%)	0.06
Median of Comorbidities (IQR)	1.0 (0.0 - 2.0)	1.0 (0.0 - 1.0)		1.0 (0.0 - 2.0)	1.0 (0.0 - 1.0)		1.0 (0.0 - 2.0)	0 (0.0 - 1.0)	
Distribution of Comorbidities - no (%)			<0.0001			0.02			0.001
0	41 (28.67%)	163 (56.40%)		12 (27.91%)	192 (49.36%)		41 (34.75%)	163 (51.91%)	
1	47 (32.87%)	70 (24.22%)		14 (32.56%)	103 (26.48%)		33 (27.97%)	84 (26.75%)	
≥2	55 (38.46%)	56 (19.38%)		17 (39.53%)	94 (24.61%)		44 (37.29%)	67 (21.34%)	

Characteristics	Mortality		P*	ICU Admission		P*	Mechanical Ventilation		P*
	Yes	No		Yes	No		Yes	No	
	N=143 (33.11%)	N = 289 (66.89%)		N=43 (9.53%)	N=389 (90.47%)		N=118 (27.31%)	N = 314 (72.69%)	
Radiologic findings									
Abnormalities on chest radiograph - no./total no. (%)									
Ground-glass opacity	110 (82.71%)	175 (71.72%)	<0.0001	35 (87.50%)	250 (74.18%)	0.06	95 (87.16%)	190 (70.90%)	
Local patchy shadowing	2 (1.24%)	43 (15.30%)	<0.0001	2 (4.76%)	43 (11.38%)	0.19	4 (3.48%)	41 (13.44%)	0.0032
Bilateral patchy shadowing	136 (97.84%)	225 (80.07%)	<0.0001	39 (92.86%)	322 (85.19%)	0.17	110 (95.65%)	251 (82.30%)	0.0004
Laboratory findings, Median (IQR)	8.9 (5.5 - 12.4)	4.8 (3.7 - 6.5)		7.2 (4.8 -11.6)	5.3 (3.9 - 7.7)		7.5 (5.5 - 11.6)	4.9 (3.7 - 6.9)	
White blood cell count, 10 ³ /L			<0.0001			0.002			<0.0001
<4	19 (13.29%)	102 (35.29%)		5 (11.63%)	116 (29.82%)		11 (9.32%)	110 (35.03%)	
4—10	71 (49.65%)	176 (60.90%)		25 (58.14%)	222 (57.07%)		66 (55.93%)	181 (57.64%)	
>10	53 (37.06%)	11 (3.81%)		13 (30.23%)	51 (13.11%)		41 (34.74%)	23 (7.32%)	
Lymphocyte count, 10 ³ /L	0.6 (0.4 - 0.9)	1.0 (0.7 - 1.4)		0.8 (0.5 - 1.1)	0.9 (0.6 -1.3)		0.7 (0.5 - 1.0)	1.0 (0.6 - 1.3)	
<0.8	103 (72.03%)	98 (33.91%)	<0.0001	23 (53.49%)	178 (45.76%)	0.33	75 (63.65%)	126 (40.13%)	<0.0001
Hemoglobin, g/dL	129 (116 - 145)	131 (122 - 144)		127 (117 - 143)	130 (121 - 144)		129 (116 - 141)	131 (121 - 144)	
Platelet count, 10 ³ /L	139 (95 - 215)	179 (139 - 236)		143 (107 - 215)	169 (130 - 232)		145.5 (100.5 - 212.5)	176.5 (133.5 - 235.5)	
Albumin, g/L	28.6 (25.4 - 32.9)	39.5 (35.5 - 43.4)		29.3 (25.3 - 34.3)	37 (30.8 - 42.2)		29 (26.0 - 32.9)	39 (34.3 - 43.3)	
ALT, U/L	35.5 (23 - 56)	23 (14 - 38)		28 (17 - 54)	26 (16 - 43)		32 (21 - 54)	25 (15 - 41)	
>40	61 (42.66%)	65 (22.49%)	<0.0001	17 (39.53%)	109 (28.02%)	0.12	45 (38.14%)	81 (25.80%)	0.009
AST, U/L	46 (32 - 72)	28 (21 - 39)		37 (28 - 53)	30 (23 - 48)		43 (29 - 60)	29 (22 - 44)	
>40	87 (60.84%)	68 (23.53%)	<0.0001	21 (48.84%)	134 (34.45%)	0.06	67 (56.78%)	88 (28.03%)	<0.0001
Total bilirubin, μmol/L	14.6 (10.3 - 21.7)	8.5 (6.3 - 11.7)		15.2 (8.8 - 22.8)	9.7 (6.9 - 14.2)		12.9 (8.8 - 20.1)	9.1 (6.5 - 13.1)	
>17.1	57 (39.86%)	26 (9%)	<0.0001	18 (41.86%)	65 (16.71%)	<0.0001	38 (32.20%)	45 (14.33%)	<0.0001
Creatinine, μmol/L	83.3 (66.3-109.5)	69.2 (58 - 80)		73.5 (52.8- 91.5)	73 (59 - 87)		77.6 (60.3 - 98.1)	72 (84.5 - 82.9)	

>133	28 (19.58%)	9 (3.11%)	<0.0001	3 (6.98%)	34 (8.74%)	0.69	20 (16.95%)	17 (5.41%)	<0.0001
Lactate dehydrogenase, U/L	547.5 (390 - 731)	231.5 (176 - 307)		470 (298 - 807)	269 (196 - 449)		493 (346 - 652)	243 (179 - 364)	
Creatine kinase, U/L	136 (70 - 314)	70 (46 - 123.9)		106.5 (63 - 156)	82 (49.5 - 164)		123 (65 - 278)	77 (48.6 - 144)	
>185	47 (32.87%)	39 (13.49%)	<0.0001	8 (18.6%)	78 (20.05%)	0.82	34 (28.81%)	52 (16.52%)	0.0045
Prothrombin time, s	14.7 (13.7 - 16.1)	13.7 (12.9 - 14.6)	<0.0001	14 (13 - 16.2)	14 (13 - 15)	0.003	14.4 (13 - 15.8)	14 (13 - 14.8)	
<16	107 (74.83%)	267 (92.39%)		31 (72.09%)	343 (88.17%)		92 (77.97%)	282 (89.81%)	0.0013
≥16	36 (25.17%)	22 (7.61%)		12 (27.91%)	46 (11.83%)		26 (22.03%)	32 (10.19%)	
D-dimer, µg/L	6.0 (1.5 - 8.0)	1.0 (0.3 - 1.8)	<0.0001	2.5 (0.7 - 6.9)	1.4 (0.6 - 3.0)	0.04	3.6 (0.7 - 8.0)	1.2 (0.5 -2.2)	0.0348
<0.5	19 (13.29%)	115 (39.79%)		6 (13.95%)	128 (32.90%)		27 (22.88%)	107 (34.08%)	
0.5 – 1	19 (13.29%)	47 (16.26%)		8 (18.60%)	58 (14.91%)		16 (13.56%)	50 (15.92%)	
>1	105 (73.43%)	127 (43.94%)		29 (67.44%)	203 (52.19%)		75 (63.56%)	157 (50.00%)	
Minerals									
Median sodium (IQR) mmol/L	137.3 (134.9-140.7)	136.9 (134.5-139)		138.7 (135.8 - 141.7)	136.8 (134.5 - 139)		138.0 (135.7 - 141.6)	136.6 (134-139)	
Median potassium (IQR) mmol/L	3.9 (3.5 - 4.4)	4.0 (3.1 - 5.2)		3.8 (3.5 - 4.3)	4.0 (3.6 - 4.3)		3.8 (3.5 - 4.3)	4.0 (3.7 - 4.3)	

Characteristics	Mortality		P*	ICU Admission		P*	Mechanical Ventilation		P*
	Yes	No		Yes	No		Yes	No	
	N=143 (33.11%)	N = 289 (66.89%)		N=43 (9.53%)	N=389 (90.47%)		N=118 (27.31%)	N = 314 (72.69%)	
Organ failure									
Median of Organ failure (IQR)									
Distribution of Organ failure - no (%)			<0.0001			0.07			<0.0001
0	3 (2.10%)	129 (44.64%)		8 (18.60%)	124 (31.88%)		13 (11.02%)	119 (37.97%)	
≥1	140 (97.90%)	160 (55.36%)		35 (81.40%)	265 (68.12%)		105 (88.98%)	195 (62.03%)	
Sepsis -- no./total no. (%)	49 (34.27%)	0	<0.0001	11 (26.19%)	38 (9.77%)	0.0003	30 (25.42%)	19 (6.07%)	<0.0001
Shock -- no./total no. (%)	106 (74.13%)	1 (0.15%)	<0.0001	20 (47.62%)	87 (22.37%)	0.0003	66 (55.93%)	41 (13.10%)	<0.0001
Treatments -- no./total no. (%)									
ECMO	2 (1.41%)	2 (0.69%)	0.47	1 (2.33%)	3 (0.77%)		3 (2.54%)	1 (0.32%)	0.03
Oxygen therapy	91 (63.64%)	178 (61.59%)	<0.0001	30 (69.77%)	248 (63.75%)	0.41	NA	NA	
Mechanical ventilation	92 (64.34%)	26 (9.0%)	<0.0001	25 (58.14%)	93 (78.81%)	<0.0001	NA	NA	
Renal replacement therapy	16 (16.19%)	0 (0.00%)	<0.0001	12 (27.91%)	4 (1.03%)	<0.0001	11 (9.32%)	5 (1.59%)	<0.0001
Glucocorticoid therapy									
Metacortandracin	27(23.68%)	23(21.50%)	<0.001	10(27.03%)	49(26.63%)	<0.001	17(19.54%)	26(19.40%)	<0.001
Methylprednisolone	31(27.19%)	29(27.10%)	<0.001	11(29.73%)	55(29.89%)	<0.001	27(31.03%)	42(31.34%)	<0.001
Hydrocortisone	35(30.71%)	32(29.90%)	<0.001	9(24.32%)	45(24.46%)	<0.001	23(26.44%)	36(26.87%)	<0.001
Dexamethasone	21(18.42%)	23(21.50%)	<0.001	7(18.92%)	35(19.02%)	<0.001	20(22.99%)	30(22.39%)	<0.001
Immunoglobulin therapy	71 (50%)	56 (19.51%)	<0.0001	26 (61.90%)	101 (26.10%)	<0.0001	51 (43.97%)	76 (24.28%)	<0.0001
Antibiotic therapy	131 (92.25%)	241 (83.97%)	0.02	41 (97.62%)	331 (85.51%)	0.03	270 (86.26%)	102 (87.93%)	0.65
Antiviral therapy	134 (94.37%)	266 (92.68%)	0.51	40 (95.24%)	360 (93.02%)	0.59	109 (93.97%)	291 (92.97%)	0.72

393 * Mann-Whitney U test, χ^2 test, or Fisher's exact test

394 **Table 2. Factors Associated with CFR, ICU Admission and Mechanical Ventilation**

	CFR^a	ICU Admission^b	Mechanical Ventilation^c
	HR (95% CI)	OR (95% CI)	OR (95% CI)
Age			
≤ 50 yr	Ref	Ref	Ref
51—65 yr	1.72 (0.86 - 3.42)	1.29 (0.39 - 4.27)	1.73 (0.73 - 4.10)
≥ 66 yr	2.09 (1.02 - 4.25)	1.48 (1.07 - 2.05)	4.30 (1.83 - 10.13)
Sex			
Male	Ref	Ref	NA
Female	0.98 (0.63 - 1.52)	0.95 (0.38 - 2.37)	NA
COVID-19 Severity			
Non-severe	Ref	NA	NA
Severe	5.02 (2.05 - 12.29)	NA	NA
Smoking history			
Never smoked	Ref	NA	Ref
Current smoker	1.67 (1.37 - 2.02)	NA	2.72 (1.67 - 4.44)
Fever on admission			
<37.5 °C	Ref	NA	Ref
37.5 - 39.0 °C	1.11 (0.64 - 1.91)	NA	0.58 (0.21 - 1.60)
>39.0 °C	2.68 (1.88 - 4.23)	NA	1.60 (0.58 - 2.28)
Symptoms			
0-2	Ref	NA	Ref
3-5	0.79 (0.36 - 1.74)	NA	0.57 (0.10 - 1.05)
≥6	0.62 (0.28 - 1.39)	NA	0.49 (0.18 - 1.32)
Comorbidities - no. (%)			
0	Ref	Ref	Ref
1	0.91 (0.56 - 1.46)	2.06 (0.73 - 5.85)	1.41 (0.67 - 2.98)
≥2	2.12 (1.62 - 3.09)	3.33 (1.15 - 9.63)	1.83 (1.40 - 2.72)
Radiologic findings			
Ground-glass opacity	Ref	Ref	Ref
Bilateral patchy shadowing	3.74 (1.78 - 9.62)	3.25 (1.68 - 7.48)	2.84 (1.83 - 4.07)
White blood cell count, × 10⁹ per L			
<4	Ref	Ref	Ref
4—10	1.06 (0.59 - 1.92)	3.12 (1.61 - 13.90)	5.13 (2.12 - 12.41)
>10	2.19 (1.11 - 4.31)	7.56 (3.66 - 19.96)	19.93 (6.62 - 60.02)

Lymphocyte count, x 10⁹ per L

<0.8	Ref	NA	Ref
≥0.8	0.65 (0.41 - 1.02)	NA	0.88 (0.43 - 1.80)

ALT, U/L

≤40	Ref	NA	Ref
>40	1.33 (0.85 - 2.09)	NA	1.65 (0.78 - 3.53)

AST, U/L

≤40	Ref	NA	Ref
>40	0.74 (0.46 - 1.18)	NA	1.72 (0.81 - 3.69)

Total bilirubin, μmol/L

≤17.1	Ref	Ref	Ref
>17.1	0.56 (0.36 - 0.87)	0.52 (0.20 - 1.39)	1.72 (0.81 - 3.69)

Creatinine, μmol/L

≤133	Ref	NA	Ref
>133	0.95 (0.58 - 1.57)	NA	1.12 (0.43 - 2.88)

Creatine kinase, U/L

≤185	Ref	NA	Ref
>185	0.47 (0.30 - 0.73)	NA	0.88 (0.43 - 1.80)

Prothrombin time, s

<16	Ref	Ref	Ref
≥16	0.92 (0.57 - 1.48)	2.51 (0.87 - 7.19)	1.67 (0.69 - 4.02)

D-dimer, μg/L

<0.5	Ref	Ref	Ref
0.5 - 1	1.64 (0.77 - 3.50)	1.60 (0.37 - 6.87)	1.48 (0.23 - 2.03)
>1	1.87 (1.03 - 3.38)	1.54 (0.48 - 4.87)	1.63 (0.24 - 2.68)

Organ failure

0	Ref	NA	Ref
≥1	6.47 (1.97 - 21.23)	NA	2.45 (1.04 - 5.81)

Treatments

Mechanical ventilation	2.30 (1.46 - 3.63)	2.16 (0.85 - 5.49)	NA
Glucocorticoid therapy	1.60 (1.04 - 2.30)	4.92 (1.37 - 17.64)	2.35 (1.14 - 4.82)
Immunoglobulin therapy	0.91 (0.59 - 1.40)	2.80 (1.16 - 6.75)	2.13 (0.82 - 3.01)
Antibiotic therapy	2.11 (0.73 - 9.13)	NA	1.74 (0.61 - 3.42)
Antiviral therapy	1.15 (0.80 - 3.57)	NA	1.37 (0.46 - 3.05)

396 b. and c. Multivariable logistic regression model to identify factors associated with ICU admission and mechanical ventilation;
397 adjusted odds ratios (AOR) and 95% confidence intervals (CI) are reported

398 Abbreviation: CFR, case fatality rate